Progression of ductal carcinoma in situ: The pathological perspective

Breast Cancer Research

Volumn 8, Issue 2, 2006, Pages

  Jones, J Louise ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST NEOPLASMS; DISEASE COURSE; FEMALE; HUMAN; INTRADUCTAL CARCINOMA; PATHOLOGY;

BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; DISEASE PROGRESSION; FEMALE; HUMANS;

EID: 34948882960     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr1397     Document Type: Review

References (27)

1. Ernster VL, Barclay J, Kerlikowske K, Wilkie H, Ballard-Barbash R: Mortality among women with ductal carcinoma in situ of the breast in the population-based surveillance, epidemiology and end results program. Arch Intern Med 2000, 160:953-958.
2. Van Dongen JA, Fentiman IS, Harris JR, Holland R, Peterse JL, Salvadori B, Stewart HJ: InTsitu breast cancer: the EORTC consensus meeting. Lancet 1989, ii:25-27.
3. Schnitt SJ: Flat epithelial atypia - classification, pathologic features and clinical significance. Breast Cancer Res 2003, 5: 263-268.
4. Saunders ME, Schuyler PA, Dupont WD, Page DL: The natural history of low grade ductal carcinoma in situ of the breast in women treated by biopsy only revealed over 30 years of longterm follow-up. Cancer 2005, 103:2481-2484.
5. Collins LC, Tamimi RM, Baer HJ, Connoly JL, Colditz GA, Schnitt SJ: Outcome of patients with ductal carcinoma in situ untreated after diagnostic biopsy Results from the Nurses' Health Study. Cancer 2005, 103:1778-1784.
6. Van Dongen JA, Holland R, Peterse JL, Fentiman IS, Lagios MD, Millis RR, Recht A: Ductal carcinoma in situ Sf the breast: second EORTC consensus meeting. Eur J Cancer 1992, 28: 626-629.
7. Silverstein MJ, Lagios MD, Craig PH, Waisman JR, Lewinsky BS, Colburn WJ, Poller DN: A prognostic index for ductal carcinoma in situ of the breast. Cancer 1996, 77:2267-2274.
8. National Coordinating Group for Breast Screening Pathology: Guidelines for Pathology Reporting in Breast Cancer Screening. 3rd edition. Sheffield: NHSBSP Publications; 2005.
9. Badve S, A'Hern RP, Ward AM, Millis RR, Pinder SE, Ellis IO, Gusterson BA, Sloane JP: Prediction of local recurrence of ductal carcinoma in situ of the breast using five histological classifications: A comparative study with long follow-up. Hum Pathol 1998, 29 915-923.
10. Skinner KA, Silverstein MJ: The management of ductal carcinoma in situ of the breast. Endocr Relat Cancer 2001, 8:33-45.
11. Bijker N, Peterse JL, Julien J-P, Fentimen IS, Duval C, Di Palma S, Simony-Lafontaine J, de Mascarel I, van de Vijver M: Risk factors for recurrence and metastasis after breast conserving therapy for ductal carcinoma in-situ: Analysis of European organisation for research and treatment of cancer trial 10853. J Clin Oncol 2001, 19 2263-2271.
12. Silverstein MJ, Lagios MD, Groshen S, Waisman JR, Lewinsky BS, Martino S, Gamagami P, Colburn WJ: The influence of margin width on local control of ductal carcinoma in situ of the breast. N Eng J Med 1999, 340:1455-1461.
13. Millis RR, Ryder K, Fentiman IS: Ductal carcinoma in situ and prognosis in invasive mammary carcinoma. Breast Cancer Res Treat 2004, 84:197-198.
14. Simpson PT, Reis-Filho JS, Gale T, Lakhani SR: Molecular evolution of breast cancer. J Pathol 2005, 205:248-254.
15. Betsill WLJ, Rosen PP, Lieberman PH, Robbins GF: Intraductal carcinoma. Long tern follow-up after treatment by biopsy alone. J Am Med Assoc 1978, 239:1863-1867.
16. Eusebi V, Feudale E, Foschini MP, Micheli A, Conti A, Riva C, Di Palma S, Rilke F: Long-term follow-up of in-situ carcinoma of the breast Semin Diag Pathol 1994, 11:223-235.
17. Cornfield DB, Palazzo JP, Schwartz GF, Goonewardene SA, Kovatich AJ, Chervoneva I, Hyslop T, Schwarting R: The prognostic significance of multiple morphologic features and biologic markers in ductal carcinoma in situ of the breast. A study of a large cohort of patients treated with surgery alone. Cancer 2004, 100:2317-2327.
18. Ringberg A, Anagnostaki L, Anderson H, Idvall I, Ferno M: Cell biological factors in ductal carcinoma in situ (DCIS) of the breast - relationship to ipsilateral local recurrence and histopathological characteristics. Eur J Cancer 2001, 37:1514- 1522.
19. Done SJ, Eskandarain S, Bull S, Redson M, Andrulis IL: p53 missense mutation in microdissected high grade ductal carcinoma in situ of the breast. J Natl Cancer Inst 2001, 93: 700-704.
20. Barnes NLP, Khavari S, Boland GP, Cramer A, Knox WF, Bundred NJ: Absence of HER4 expression predicts recurrence of ductal carcinoma in situ of the breast. Clin Cancer Res 2005, 11:2163-2168.
21. Sartor CI, Zhou H, Kozlowska E, Guttridge K, Kawata E, Caskey L, Harrelson J, Hynes N, Ethier S, Calvo B, Earp HS: HER4 mediates ligand dependent antiproliferative and differentiation responses in human breast cancer cells. Mol Cell Biol 2001, 21 4265-4275.
22. Ma XJ, Salunga R, Tuggle JT, Gaudet J, Enright E, McQuary P, Payette T, Pistone M, Stecker K, Zhang BM, et al.: Gene expression profiles of breast cancer progression. Proc Natl Acad Sci USA 2003, 100:5974-5979.
23. Weigelt B, Wessels LFA, Bosma AJ, Glas AM, Nuyten DSA, He YD, Dai H, Peterse JL, van't Veer LJ: No common denominator for breast cancer lymph node metastasis. Br J Cancer 2005, 93:924-932.
24. Tot T: DCIS, cytokeratins and the theory of the sick lobe. Virchows Arch 2005, 447:1-8.
25. Adams M, Jones JL, Walker RA, Pringle JH, Bell SC: Altered Tenascin-C isoform expression in invasive and pre-invasive breast cancer. Cancer Res 2002, 62:3289-3297.
26. Allinen M, Beroukhim R, Cal LI, Brennan C, Lahti-Domenici J, Huang H, Porter D, Hu M, Chin L, Richardson A, et al.: Molecular characterisation of tumour microenvironment in breast cancer. Cancer Cell 2004, 6:17-32.
27. Nielsen BS, Rank F, Lopez JM, Balbin M, Vizoso F, Lund LR, Dano K, Lopez-Otin C: Collagenase-3 expression in breast myofibroblasts as a molecular marker of transition of ductal carcinoma in-situ lesions to invasive ductal carcinomas. Cancer Res 2001, 61:7091-7100.